Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14509638 | 0.82 | ATM (0.77) | ATML3MBTL1KMT2ANAMPTPIK3CD | |
| SCHEMBL17203603 | 0.82 | ATM (0.77) | ATML3MBTL1KMT2ANAMPTPIK3CD | |
| SCHEMBL6034582 | 0.81 | ATM (0.97) | ATML3MBTL1KMT2ANAMPTPIK3CD | |
| SCHEMBL10496019 | 0.81 | ATM (0.76) | ATML3MBTL1KMT2ANAMPTPIK3CD | |
| SCHEMBL5250912 | 0.80 | ATM (0.75) | ATML3MBTL1KMT2ANAMPTALDH1A1 | |
| SCHEMBL27601593 | 0.80 | KMT2A (0.55) | ATML3MBTL1KMT2ANAMPTPIK3CD | |
| SCHEMBL2708828 | 0.77 | ATM (0.55) | ATML3MBTL1KMT2ANAMPTPIK3CD | |
| SCHEMBL17213926 | 0.76 | ATM (0.71) | ATML3MBTL1KMT2ANAMPTPIK3CD | |
| SCHEMBL10496006 | 0.76 | L3MBTL1 (0.72) | ATML3MBTL1KMT2ANAMPTALDH1A1 | |
| SCHEMBL2848208 | 0.74 | ATM (0.63) | ATML3MBTL1KMT2ANAMPTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | claimed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| CN-100519550-C | 2-oxoindole compounds having inhibitory activity on glycogen synthase kinase 3 receptor | ASTRAZENECA AB SE (SE) | 2009-07-29 | — | — | CN | disclosed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | disclosed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | disclosed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | ATM 4200/4885L3MBTL1 4876/4885KMT2A 4694/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | ATM 4332/4885L3MBTL1 4869/4885KMT2A 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.